Estimulación del nervio vago para la artritis reumatoide de moderada a grave (RESET-RA)
Estimulación del nervio vago con el sistema SetPoint para la artritis reumatoide de moderada a grave: el estudio RESET-RA
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Mesa, Arizona, Estados Unidos, 85210
- Arizona Arthritis ans Rheumatology Research, PPLC
-
Phoenix, Arizona, Estados Unidos, 85037
- Arizona Arthritis Rheumatology & Research, PLLC
-
Tucson, Arizona, Estados Unidos, 85704
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Covina, California, Estados Unidos, 91722
- Medvin Clinical Research
-
Upland, California, Estados Unidos, 91786
- Inland Rheumatology Clinical Trials
-
Whittier, California, Estados Unidos, 90602
- Medvin Clinical Research
-
-
Colorado
-
Fort Collins, Colorado, Estados Unidos, 80528
- The Arthritis & Rheumatology Clinic of Northern Colorado
-
-
Connecticut
-
Stamford, Connecticut, Estados Unidos, 06905
- Stamford Therapeutics Consortium
-
-
Delaware
-
Lewes, Delaware, Estados Unidos, 19958
- Delaware Arthritis
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- Arthritis & Rheumatic Disease Specialties
-
Avon Park, Florida, Estados Unidos, 33825
- HARAC Research Corporation
-
Boynton Beach, Florida, Estados Unidos, 33472
- RecioMed Clinical Research Network, Inc.
-
Clearwater, Florida, Estados Unidos, 33765
- Bay Area Rheumatology
-
Plantation, Florida, Estados Unidos, 33324
- IRIS Research and Development
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30912
- Augusta University
-
Lawrenceville, Georgia, Estados Unidos, 30044
- Parris and Associates Rheumatology
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Willowbrook, Illinois, Estados Unidos, 60527
- Willow Rheumatology and Wellness PLLC
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
-
-
Michigan
-
Lansing, Michigan, Estados Unidos, 48910
- June DO, PC
-
-
Minnesota
-
Eagan, Minnesota, Estados Unidos, 55121
- Saint Paul Rheumatology, P.A.
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64151
- Kansas City Physician Partners
-
St Louis, Missouri, Estados Unidos, 63122
- West County Rheumatology
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68516
- Physician Research Collaboration, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87102
- Albuquerque Center for Rheumatology
-
-
New York
-
Babylon, New York, Estados Unidos, 11702
- Long Island Regional Arthritis & Osteoporosis Care
-
-
North Carolina
-
Charleston, North Carolina, Estados Unidos, 28202
- Arthritis & Osteoporosis Consultants Of The Carolinas
-
Charlotte, North Carolina, Estados Unidos, 28210
- DJL Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73103
- Health Research of Oklahoma, PLLC
-
Oklahoma City, Oklahoma, Estados Unidos, 73116
- Rheumatology Associates of Oklahoma
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Lehigh Valley Health Network
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania Medical Center
-
-
Texas
-
Allen, Texas, Estados Unidos, 75013
- Arthritis & Rheumatology Research Institute, PLLC
-
Austin, Texas, Estados Unidos, 78745
- Tekton Research
-
Austin, Texas, Estados Unidos, 78717
- Austin Regional Clinic
-
Austin, Texas, Estados Unidos, 78746
- Central Texas Rheumatology Associates
-
Colleyville, Texas, Estados Unidos, 76034
- Precision Comprehensive Clinical Research Solutions
-
Houston, Texas, Estados Unidos, 77043
- Biopharma Informatic
-
Mesquite, Texas, Estados Unidos, 75150
- Southwest Rheumatology Research LLC
-
San Antonio, Texas, Estados Unidos, 78229
- Clinical Trials of Texas, Inc
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22033
- Annapolis Rheumatology
-
-
Washington
-
Bothell, Washington, Estados Unidos, 98021
- Sound Clinical Research, LLC
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 22-75 years of age at screening
- Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
- Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
- Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12
Exclusion Criteria:
- Untreated or poorly controlled psychiatric illness or history of substance abuse
- Significant immunodeficiency due to underlying illness
- History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
- Clinically significant cardiovascular disease
- Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
- Uncontrolled fibromyalgia
- History of left or right carotid surgery
- History of unilateral or bilateral vagotomy, partial or complete splenectomy
- Recurrent vasovagal syncope episodes
- Current, regular use of tobacco products
- Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Treatment
Active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Otros nombres:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Otros nombres:
Active stimulation for 1 min once per day |
|
Comparador falso: Control
Non-active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Otros nombres:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Otros nombres:
Non-active stimulation for 1 min once per day |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
the American College of Rheumatology (ACR) 20 Response
Periodo de tiempo: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Periodo de tiempo: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 A subject is considered having a moderate treatment response if:
A subject is considered having a good treatment response if: • DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2 |
Week 12
|
|
DAS28-CRP Response (MCID -1.2) at Week 12
Periodo de tiempo: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline. DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 |
Week 12
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Periodo de tiempo: Week 12
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 12
|
|
ACR20 Response at Week 12 From Day 0
Periodo de tiempo: Week 12
|
Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL). |
Week 12
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Bone Erosion Progression, All Completers
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Change in Erosion Score, All Completers
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Synovitis Score, All Completers
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Osteitis Score, All Completers
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers With Erosive Phenotype
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Periodo de tiempo: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Periodo de tiempo: Week 12
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 12
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission
Periodo de tiempo: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Periodo de tiempo: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Periodo de tiempo: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Periodo de tiempo: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Periodo de tiempo: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Periodo de tiempo: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Periodo de tiempo: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Periodo de tiempo: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Periodo de tiempo: Week 24
|
Patients were asked a question about whether they would recommend the SetPoint System to family and friends |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Periodo de tiempo: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Periodo de tiempo: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Periodo de tiempo: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Periodo de tiempo: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Periodo de tiempo: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Periodo de tiempo: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Periodo de tiempo: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Periodo de tiempo: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Periodo de tiempo: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Periodo de tiempo: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Periodo de tiempo: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Periodo de tiempo: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Periodo de tiempo: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Periodo de tiempo: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Mark Richardson, MD PhD, Massachusetts General Hospital
- Investigador principal: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.
Publicaciones y enlaces útiles
Publicaciones Generales
- Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, Ko A, Adelson PD, Lega B, Konrad P, Calle G, Vale FL, Bucholz R, Richardson RM. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024 Mar 13;10(1):8. doi: 10.1186/s42234-023-00138-x.
- Tesser JRP, Crowley AR, Box EJ, June JP, Wickersham PB, Valenzuela GJ, Gaylis NB, Lam GKW, Pacheco LA, Ridley DJ, Pinto-Patarroyo GP, Novack SN, Churchill MA, Kohler M, Lee EC, Pando JA, Parris GR, Peterson JR, Shah T, Singhal AK, Vuong V, Levine YA, Evangelista ML, Derosier AA, Curtis JR, Richardson RM, Chernoff D. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nat Med. 2026 Jan;32(1):369-378. doi: 10.1038/s41591-025-04114-7. Epub 2025 Dec 22.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Artritis
- Enfermedades Articulares
- Enfermedades reumáticas
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades de la piel y del tejido conectivo
- Artritis Reumatoide
- Preparaciones farmacéuticas
- Formas de dosificación
- Preparaciones de acción retrasada
- Implantes de drogas
Otros números de identificación del estudio
Otros números de identificación del estudio
- SPM-020
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
No sharing data is planned.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .